In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy
C. Dureja, J. T. Rutherford, F. B. A. Pavel, K. Norseeda, I. Prah, D. Sun, K. E. Hevener, J. G. Hurdle
This study evaluates the in vivo efficacy of phenylimidazole 296 against C. difficile by targeting CdFabK, showing it retains microbiome stability better than vancomycin and fidaxomicin.
bioRxiv · Sep 22, 2023 · PreprintMicrobiology